Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with Intas Pharmaceuticals for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use ...
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. - for the commercialization of Foresee's novel FP-001..
Foresee Pharmaceuticals Co., Ltd. announced that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the U.S. Food and Drug ...